Production of induced pluripotent stem cells from renal epithelial cells with a novel collection kit
Induced pluripotent stem cells have been generated from a new renal epithelial cell collection kit that was developed at McGill University.
Induced pluripotent stem cell (iPSC) technology allows generation of pluripotent stem cells from somatic cells bearing any genomic background, with the most common being skin and blood. Unfortunately, skin iPSC take a long time to generate and also require medical intervention and aftercare. Blood iPSC can be produced in a shorter amount of time, but the cost of production is much higher. The current challenge is therefore how to translate human iPSC protocols into a viable clinical treatment.
This technology is a urine collection kit to isolate renal epithelial cells for the purpose of making iPSC. After the non-invasive collection of renal epithelial cells, the cells remain viable for 48 hours at room temperature and stable iPSC can be grown in two weeks. Compared to the production of iPSC from blood and skin cells, generation of iPSC from renal cells can be completed in a shorter amount of time and for less money. The use of human iPSC in the clinical setting is definitely growing, as some countries are even setting up programs to generate HLA-typed cell banks. With the low cost, ease of collection, and high iPSC cell quality, this kit could become an important tool for those programs.
- Generation of stable iPSC 2 weeks after renal cell collection
- Cell viability in the collection tube is maintained for 48 hours at room temperature
- Collection can be performed by a non-expert outside of a clinical setting
Background IP for Research Opportunity